Keymed Biosciences Inc
Company Profile
Business description
Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. Its clinical-stage drug candidates include CM310, CM326, CM313, and CM336 among others. The company is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it generates a majority of its revenue from overseas markets and the rest from Mainland China.
Contact
No. 18 BioTown Middle Road
Building D2
Tianfu International BioTown, Chengdu
Sichuan610219
CHNT: +86 2888610620
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
1,469
Stocks News & Analysis
stocks
ASX retail share remains cheap despite weaker earnings
stocks
AI isn’t an economic moat killer, but it will disrupt industries
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,726.50 | 32.00 | -0.37% |
| CAC 40 | 7,801.77 | 44.78 | -0.57% |
| DAX 40 | 22,673.66 | 283.42 | -1.23% |
| Dow JONES (US) | 46,429.49 | 305.43 | 0.66% |
| FTSE 100 | 10,015.78 | 91.06 | -0.90% |
| HKSE | 24,856.43 | 479.52 | -1.89% |
| NASDAQ | 21,929.82 | 167.93 | 0.77% |
| Nikkei 225 | 53,603.65 | 145.97 | -0.27% |
| NZX 50 Index | 12,976.99 | 47.69 | 0.37% |
| S&P 500 | 6,591.90 | 35.53 | 0.54% |
| S&P/ASX 200 | 8,525.70 | 21.30 | -0.25% |
| SSE Composite Index | 3,889.08 | 42.75 | -1.09% |